Top Story

Growth estimated in B-cell NHL treatment market value

August 30, 2014

The market value of B-cell non-Hodgkin’s lymphoma treatments will experience moderate growth across six major markets from $4.59 billion in 2013 to $5.41 billion by 2018, according to a report from GlobalData.

The research and consulting firm said that with the recent FDA approval of targeted B-cell receptor inhibitors ibrutinib (Imbruvica; Pharmacyclics, Janssen) and idelalisib (Zydelig, Gilead Sciences), the global NHL treatment paradigm will undergo a dramatic shift away from chemoimmunotherapy regimens.

In the Journals

R2CHOP appears highly active in DLBCL

August 29, 2014
The combination of lenalidomide and R-CHOP demonstrated considerable activity in patients with newly diagnosed diffuse large B-cell lymphoma, according to results of a…
figure In the Journals

Identification of 102 genes may help classify, treat patients with polycythemia vera

August 27, 2014
Analysis of peripheral blood cells from patients with polycythemia vera identified 102 genes concordantly expressed in men and women that may help classify patients…
In the Journals

Weekend admission increased hospital stays for children with leukemia

August 25, 2014
Children with newly diagnosed acute lymphoblastic or acute myeloid leukemia who were admitted to the hospital on weekends experienced prolonged lengths of stay, delayed…
CME

Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC

This activity is supported by an educational grant from Genentech, Inc.

8/7/2014
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, but the numerous subtypes make this disease…
More »
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

Industry News

Growth estimated in B-cell NHL treatment market value

August 30, 2014
The market value of B-cell non-Hodgkin’s lymphoma treatments will experience moderate growth across six major markets from $4.59 billion in…
In the Journals

R2CHOP appears highly active in DLBCL

August 29, 2014
The combination of lenalidomide and R-CHOP demonstrated considerable activity in patients with newly diagnosed diffuse large B-cell lymphoma…
figure In the Journals

Identification of 102 genes may help classify, treat patients with polycythemia vera

August 27, 2014
Analysis of peripheral blood cells from patients with polycythemia vera identified 102 genes concordantly expressed in men and women that may help…
In the Journals

Weekend admission increased hospital stays for children with leukemia

August 25, 2014
Children with newly diagnosed acute lymphoblastic or acute myeloid leukemia who were admitted to the hospital on weekends experienced prolonged…
In the Journals

PET/CT after one chemotherapy cycle highly prognostic in Hodgkin’s lymphoma

August 22, 2014
Negative PET/CT after one cycle of chemotherapy accurately predicted favorable outcomes among patients with Hodgkin’s lymphoma, according to…
In the Journals

Somatic mutations in myelodysplastic syndrome linked to shorter survival after HSCT

August 18, 2014
Patients with myelodysplastic syndrome who harbored TP53, TET2 or DNMT3A mutations demonstrated significantly shorter OS after allogeneic…
figure In the Journals

Genetic mutation linked to acquired ibrutinib resistance in MCL

August 15, 2014
A relapse-specific BTK genetic mutation identified in patients with mantle cell lymphoma may serve as a target to overcome both primary and acquired…
Industry News

Kyprolis fails to meet primary endpoint in multiple myeloma

August 15, 2014
Results from a phase 3 trial have found that carfilzomib did not meet its primary endpoint of OS for the treatment of relapsed and advanced…
figure In the Journals

Switch from imatinib to nilotinib improved outcomes in chronic phase CML

August 15, 2014
Patients with chronic phase chronic myeloid leukemia who had persistent minimal residual disease after long-term treatment with imatinib achieved…
figure FDA News

FDA grants fast track designation to AG-221 for IDH2-mutant AML

August 14, 2014
The FDA granted fast track designation to AG-221 as a potential treatment for patients with acute myelogenous leukemia who harbor IDH2 genetic…
More Headlines »